Description
TMP-269 is an inhibitor of class II histone deacetylases (HDACs) that exhibits anticancer activity. In intestinal epithelial cells, TMP-269 inhibits cell cycle progression and cell proliferation. In multiple myeloma cells, this compound enhances carfilzomib-induced apoptosis.